

Drug Prior Authorization Form Praluent (alirocumab)

The purpose of this form is to obtain information required to assess your drug claim. For additional information regarding Prior Authorization and Health Case Management, please visit our Great-West Life website at www.greatwestlife.com.

IMPORTANT: Please answer all questions. Your claim assessment will be delayed if this form is incomplete or contains errors.

Any costs incurred for the completion of this form are the responsibility of the plan member/patient.

Great-West Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have questions about Great-West Life's personal information policies and practices (including with respect to service providers), refer to www.greatwestlife.com or write to Great-West Life's Chief Compliance Officer.

I authorize Great-West Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of government benefits or patient assistance programs or other benefits programs, other organizations, or service providers working with Great-West Life or any of the above, located inside or outside Canada, to exchange personal information when relevant and necessary for these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within or outside Canada.

I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan. I acknowledge that providing consent will help Great-West Life to assess my claim and that refusing to consent may result in delay or denial of my claim. Great-West Life reserves the right to audit the information provided on this form at any time and this consent extends to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.

If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information and for Great-West Life to use and disclose it as set out above.

I certify that the information given below is true, correct, and complete to the best of my knowledge. Failure to provide true, correct and complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other appropriate action.

Plan Member's signature: _____

Date: _____

Form Completion Instructions:

1. Complete "Patient Information" sections.
2. Have the prescribing physician complete the "Physician Information" sections.
3. Send all pages of the completed form to us by mail, fax or email as noted below.

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

Mail to: The Great-West Life Assurance Company
Drug Services
PO Box 6000
Winnipeg MB R3C 3A5

Fax to: The Great-West Life Assurance Company
Fax 1-204-946-7664
Attention: Drug Services

Email to: gwldrug.services@gwl.ca
Attention: Drug Services

(Continued on next page)

Patient Information Praluent (alirocumab)

Plan Member Information – Complete all sections of this page (please print)

Plan Member:		Patient Name:	
Plan Name:	Plan Number:	Plan Member ID Number:	
Patient Date of Birth (DD/MM/YYYY):	Address (number, street, city, province, postal code):		

Please indicate preferred contact number and if there are any times when telephone contact with you about your claim would be most convenient.

May we contact you by email? (Note that some correspondence may still need to be sent by regular mail).

Yes No If yes, please provide email address: _____

Tell us if you have been on this drug before

Is the patient currently on, or previously been on Praluent? Yes No

If Yes, a) indicate start date (DD/MM/YYYY): _____

b) coverage provided by: _____

(if coverage is not provided by Great-West Life please provide pharmacy print-out showing purchase of Praluent)

Tell us if you have coverage with any other benefits plan

Does the patient have drug coverage with any other group benefits plan? Yes No

If Yes, name of other Insurance Company: _____

If other plan is with Great-West Life, tell us the plan and ID number: _____

Name of plan member: _____

Relationship to patient: _____

Provide details and attach documentation of acceptance or declination:

Tell us about any Provincial or other coverage you may have

Does the patient have coverage under a provincial program or from any other source? Yes No

If Yes, name of program or other source: _____

Provide details and attach documentation of acceptance or declination: _____

Is the patient currently receiving disability benefits for the condition for which this drug has been prescribed? Yes No

Tell us about any Patient Assistance Program you might be enrolled in

Has the patient enrolled in the patient assistance program for Praluent? Yes No

If Yes, please provide the following information:

1. Patient assistance program patient ID Number: _____

2. Patient assistance program contact person name and phone number:

Contact Name: _____ Phone Number: _____

(Continued on next page)

Physician Information Praluent (alirocumab)

Note to Physician: In order to assess a patient's claim for Praluent, we require detailed information on the patient's prescription drug history as requested below.

Attach extra information if necessary. **GENETIC TEST RESULTS ARE NOT REQUIRED**

Physician's Information (please print)

Name of prescribing physician: _____

Specialty: _____

Address (number, street, city, province, postal code): _____

Telephone Number (including area code): _____

Fax Number (including area code): _____

1. Prescribed dosage and regimen:

75mg subcutaneously every 2 weeks

150mg subcutaneously every 2 weeks

Other (please specify): _____

Provide rationale: _____

2. Health Canada indication (include date of initial diagnosis) (MM/YYYY): _____

Clinical Atherosclerotic Cardiovascular Disease (CVD)

Heterozygous Familial Hypercholesterolemia (HeFH)

Other (approved by Health Canada): _____

Complete questions 1 – 5 and Other condition (Health Canada approved)

Is this drug being prescribed in accordance with approved Health Canada indications¹?

Yes, complete questions 1 – 5 and Physician Information

No, prescribed use is not approved by Health Canada: _____

Complete questions 1 – 5 and Off-label use

¹Approved Health Canada Indications and Clinical Use for Praluent:

- Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C).

3. What is the anticipated duration of treatment with Praluent? _____

4. Where will treatment be administered? Home Physician's Office Private clinic Hospital in-patient Hospital out-patient

5. Please provide medical rationale why Praluent has been prescribed instead of an alternate drug in the same therapeutic class.

Physician's Information (continued) (please print)

Clinical Atherosclerotic Cardiovascular Disease (CVD) – Genetic test results are not required

Patient's ASCVD history:

- Acute coronary syndromes
- Stroke
- History of myocardial infarction (MI)
- Transient ischemic attack (TIA)
- Stable or unstable angina
- Peripheral arterial disease presumed to be of atherosclerotic origin
- Coronary or other arterial revascularization

Please submit the listed reports to assist with the review:

- Patient's most recent LDL-C lab result (must be current within 3 months of application)

Will the patient be following a low cholesterol diet while taking Praluent? Yes No

Heterozygous Familial Hypercholesterolemia (HeFH) – Genetic test results are not required

Indicate the metrics which were used to confirm the patient's diagnosis: (based on Simon Broome criteria)

- Total cholesterol of ≥ 7.5 mmol/L OR LDL cholesterol of ≥ 4.9 mmol/L
- Tendon xanthomas in the patient or any of the patient's 1st or 2nd degree relatives
- Family history of myocardial infarction before the age of 50 years in a second-degree relative or before age 60 years in a first-degree relative
- Family history of raised total cholesterol concentration above 7.5 mmol/L in a first- or second- degree relative

Please submit the listed reports to assist with the review:

- Lab result supporting the diagnosis of HeFH as per Simon Broome criteria (total cholesterol of ≥ 7.5 mmol/L OR LDL cholesterol of 4.9 mmol/L)
- Patient's most recent LDL-C lab result (must be current within 3 months of application)

Will patient be following a low cholesterol diet while taking Praluent? Yes No

Statin Medication History – Genetic test results are not required

Has patient been taking a maximally-tolerated dose of statin therapy for at least 4 weeks and is expected to continue on statin therapy?

- Yes Complete the Statin Medication History chart
- No Complete the Statin Medication History chart and the Statin Contraindications/Intolerance sections below

Statin Medication History Chart (for all requests) - If coverage for these drugs was not provided by Great-West Life, please submit a pharmacy printout for the last 24 months.

Name of Statin	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY)	Patient response: Reason for discontinuation, details of intolerance or failure at maximum dose must be provided
				<input type="checkbox"/> Persistent myopathy or myalgia for at least 2 weeks. <input type="checkbox"/> Myositis or Rhabdomyolysis. Please submit CK levels. <input type="checkbox"/> Other - please detail: _____
				<input type="checkbox"/> Persistent myopathy or myalgia for at least 2 weeks. <input type="checkbox"/> Myositis or Rhabdomyolysis. Please submit CK levels. <input type="checkbox"/> Other - please detail: _____
				<input type="checkbox"/> Persistent myopathy or myalgia for at least 2 weeks. <input type="checkbox"/> Myositis or Rhabdomyolysis. Please submit CK levels. <input type="checkbox"/> Other - please detail: _____

Physician's Information (continued) (please print)

Statin Contraindications (for patients who are not currently on a statin)

Please check box if any of the following conditions apply to patient:

- Pregnant or may become pregnant
- Nursing mother
- Active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal (submit supporting lab report)
- Other: _____

Statin Intolerance (for patients who are not currently on a statin)

Patient must have had a trial of ≥ 2 consecutive statins:

- At least one trial must be a rechallenge at a lower dose or lower intensity statin
- Resolution or improvement of symptoms when the statin dose was decreased or discontinued
- Reason for discontinuation, details of intolerance or failure at maximum dose must be provided in medication history chart on the previous page

Other condition (Health Canada approved) – Genetic test results are not required

Please provide any relevant information related to the disease and attach supporting documentation.

Off-label use – Genetic test results are not required

Questions 1 - 4 and the Statin Medication History Chart must be completed.

Is there evidence supporting the off-label use of Praluent? Yes No

Provide clinical literature / studies to support the request for off-label use, such as:

- At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and
- Published recommendations in evidence-based guidelines supporting its use.

Provide medical rationale why Praluent has been prescribed off-label instead of an alternative drug with an approved indication for this condition.

Provide any pertinent medical history or information to support this off-label request.

If this is a renewal request, provide documentation showing efficacy since previous request.

Physician Information Praluent (alirocumab)

Note for Physician: To be eligible for reimbursement, Great-West Life may require your patient to purchase a drug requiring prior authorization from a pharmacy designated by Great-West Life. If applicable, a health case manager will contact you with further information.

I certify that the information provided is true, correct, and complete.

Physician's Signature: _____ Date: _____

License Number: _____

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit. The completed form can be returned to Great-West Life by mail, fax, or email.

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

**Mail to: The Great-West Life Assurance Company
Drug Services
PO Box 6000
Winnipeg MB R3C 3A5**

**Fax to: The Great-West Life Assurance Company
Fax 1-204-946-7664
Attention: Drug Services**

**Email to: gwldrug.services@gwl.ca
Attention: Drug Services**